Format

Send to

Choose Destination
See comment in PubMed Commons below
Semergen. 2016 May-Jun;42(4):260-2. doi: 10.1016/j.semerg.2015.08.008. Epub 2015 Dec 1.

[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].

[Article in Spanish]

Author information

  • 1Atención Primaria, Centro de Salud Casas Ibáñez, Albacete, España; Facultad de Medicina, Universidad Católica San Antonio de Murcia (UCAM), Murcia, España; Grupo HTA SEMERGEN. Electronic address: jadivison@telefonica.net.
  • 2Servicio de Cardiología, Hospital La Paz, Madrid, España; Grupo HTA SEMERGEN.
PMID:
26653339
DOI:
10.1016/j.semerg.2015.08.008
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center